As part of ongoing efforts to strengthen its drug evaluation capacity, Hong Kong has launched a new streamlined mechanism, called “1+”, to speed up the registration of pharmaceutical products containing new chemical or biological entities for life-threatening or severely-debilitating diseases.
Hong Kong currently relies on prior approvals granted by regulators in 36 reference countries to enable local drug registrations, but...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?